Last reviewed · How we verify

High-dose epinephrine — Competitive Intelligence Brief

High-dose epinephrine (High-dose epinephrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine; adrenergic agonist. Area: Cardiovascular; Emergency Medicine.

marketed Catecholamine; adrenergic agonist Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors Cardiovascular; Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

High-dose epinephrine (High-dose epinephrine) — Icahn School of Medicine at Mount Sinai. High-dose epinephrine is a catecholamine that acts as a non-selective adrenergic agonist, stimulating alpha and beta-adrenergic receptors to increase heart rate, blood pressure, and cardiac output.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
High-dose epinephrine TARGET High-dose epinephrine Icahn School of Medicine at Mount Sinai marketed Catecholamine; adrenergic agonist Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Ephedrine-S Ephedrine-S Dalian Municipal Central Hospital marketed Sympathomimetic amine Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Ephedrine, bolus Ephedrine, bolus University of Parma marketed Sympathomimetic amine; adrenergic agonist Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Atropine sulfate and epinephrine Atropine sulfate and epinephrine Dar El Oyoun Hospital marketed Anticholinergic agent and sympathomimetic amine combination Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine)
cardiac output changes with "ephedrine" cardiac output changes with "ephedrine" University Tunis El Manar marketed Sympathomimetic amine Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
epinephrine perfusion epinephrine perfusion Central Hospital, Nancy, France marketed Sympathomimetic amine / Catecholamine Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Racemic adrenaline Racemic adrenaline Oslo University Hospital marketed Sympathomimetic amine; adrenergic agonist Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine; adrenergic agonist class)

  1. Kasr El Aini Hospital · 2 drugs in this class
  2. Aga Khan University · 1 drug in this class
  3. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  4. Ministry of Health, Spain · 1 drug in this class
  5. University of Louisville · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High-dose epinephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-epinephrine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: